advanced search

PULMONARY

PULMONARY
A NOVEL HUMAN FACTORS APPROACH FOR A NEW PLATFORM-BASED, BREATH-TRIGGERED NEBULISER
Simon Bucher, Dr Amy MacDonald and Dr John DeFoggi explain how human factors engineering is at the centre of the development of PARI’s breath-triggered eFlow® Integrated nebuliser, and consider how this approach preserves scientific rigour while avoiding redundant testing and ensuring efficient resource allocation.
PULMONARY
ACOUSTIC WAVE PLATFORM NEBULISER FOR INHALED DELIVERY OF BIOLOGIC THERAPIES
Dr Elijah Nazarzadeh reports on the applications of Nebu~Flow, an acoustic wave-based nebuliser platform, addressing the challenges associated with drug delivery to the lungs via more efficient aerosolisation, enabling precise inhaled delivery of life-changing treatments.
REINVENTING THE pMDI: EVOLVING A PROVEN PLATFORM FOR A LOW-GWP FUTURE
SUSTAINABILITY
Chris Baron
Aptar Pharma
REINVENTING THE pMDI: EVOLVING A PROVEN PLATFORM FOR A LOW-GWP FUTURE
Chris Baron discusses how lower-global warming potential pressurised metered dose inhalers are moving from development to commercialisation and explains why manufacturing readiness and supply resilience are critical, going on to introduce Aptar Pharma’s ZEN30 Futurity®, designed to anticipate current and emerging regulatory expectations.
ENABLING A SUSTAINABLE FUTURE FOR pMDIs WITH LOW-GWP MEDICAL PROPELLANTS
EXPERT VIEW
Markus Laubscher
ENABLING A SUSTAINABLE FUTURE FOR pMDIs WITH LOW-GWP MEDICAL PROPELLANTS
Markus Laubscher discusses the role of pressurised metered dose inhalers in the context of healthcare’s drive towards sustainability, considering the need for lower-global-warming-potential propellants and why it is important to preserve these inhalers as a key aspect of respiratory care.
THE PHYSICS OF THE SWITCH: OPTIMISING pMDI DESIGN FOR LOW-CARBON LUNG DELIVERY
SUSTAINABILITY
Thomas Daly
Bespak
THE PHYSICS OF THE SWITCH: OPTIMISING pMDI DESIGN FOR LOW-CARBON LUNG DELIVERY
Thomas Daly and Tony Mallett discuss the transition to low-global warming potential propellants, examining the vital adjustments to the whole inhalation system necessary to support effective and safe dosing without hydrofluorocarbons.
Interview: Inside The Crux Technology Centre
INDUSTRIALISATION
Stephen Gilmore
Crux Product Design
Interview: Inside The Crux Technology Centre
Stephen Gilmore discusses the opportunities and capabilities unlocked by Crux’s new Technology Centre located in Bristol, UK. Mr Gilmore provides an overview of the new capabilities provided by the facility and the potential it represents to the future of the company.
HOW SOFT MIST INHALERS WILL BREATHE NEW LIFE INTO DRUG DEVELOPMENT
PULMONARY
Kasim Yilginc
GAPLAST
HOW SOFT MIST INHALERS WILL BREATHE NEW LIFE INTO DRUG DEVELOPMENT
Kasim Yilginc discusses the expanding importance and influence of the respiratory sector within pharmaceutical pipelines, including the role that soft mist inhalers are poised to play in improving patient outcomes and how GAPLAST’s AirlessMotion® bag-in-bottle technology can support the development of these inhalation devices.
AUTOMATING MDI ACTUATION: PRECISION DATA WITH LESS EFFORT
PULMONARY
Paul Martin
Copley Scientific
AUTOMATING MDI ACTUATION: PRECISION DATA WITH LESS EFFORT
Paul Martin considers how automation can enhance testing for metered dose inhalers by removing the variability in actuation technique introduced by manual operation, presenting two case studies that demonstrate this potential improvement in data quality.
INTRANASAL DRUG DELIVERY: FORMULATION, DEVICE DESIGN & CHARACTERISATION STRATEGIES
EXPERT VIEW
Dr Matthew Owen
INTRANASAL DRUG DELIVERY: FORMULATION, DEVICE DESIGN & CHARACTERISATION STRATEGIES
Dr Matthew Owen reviews the formulation and device challenges, designs and considerations that are shaping the nasal delivery market.
THE IMPORTANCE OF MESH NEBULISER CONFIGURATION IN mRNA-LNP DELIVERY PERFORMANCE
CGT
Hanna Beike
PARI
THE IMPORTANCE OF MESH NEBULISER CONFIGURATION IN mRNA-LNP DELIVERY PERFORMANCE
Hanna Beike and Dr Benjamin Heine highlight the superior performance of customisable drug-specific nebuliser platforms, such as eFlowM® Open System and eFlow® Integrated, for the delivery of messenger RNA-based inhalation therapies.
CHARTING THE COURSE FOR PULMONARY DRUG DEVELOPMENT
PULMONARY
Carolyn Berg
Catalent Pharma Solutions
CHARTING THE COURSE FOR PULMONARY DRUG DEVELOPMENT
Carolyn Berg and Dr Alan Watts examine strategy considerations that can help emerging biotech companies navigate early-stage pulmonary drug development, providing practical guidance for addressing challenges of respiratory delivery and avoiding common pitfalls that can derail development programmes.
Interview: Aptar Pharma Expansion With New R&D Center
INTERVIEW
Christophe Pierre
Aptar Pharma
Interview: Aptar Pharma Expansion With New R&D Center
In this interview, Christophe Pierre introduces Aptar Pharma’s new R&D Center in France, and outlines how the new facility will assist the development of smarter, more integrated drug delivery solutions, facilitating progression from concept to full-scale industrialisation across multiple therapeutic fields.
RESPIRATORY MUCOSAL VACCINATION: HOW COULD WE DELIVER ANOTHER GLOBAL VACCINATION RESPONSE WITH CURRENT DEVICE TECHNOLOGIES?
EXPERT VIEW
Mark Parry
RESPIRATORY MUCOSAL VACCINATION: HOW COULD WE DELIVER ANOTHER GLOBAL VACCINATION RESPONSE WITH CURRENT DEVICE TECHNOLOGIES?
Mark Parry discusses the potential needs and opportunities for respiratory drug delivery devices in the context of a hypothetical global vaccination strategy, considering a variety of factors and how different respiratory device approaches could perform.
STRESS-TESTING INHALED MEDICINE SO PATIENTS CAN BREATHE EASIER
EXPERT VIEW
Dr Yannick Baschung
STRESS-TESTING INHALED MEDICINE SO PATIENTS CAN BREATHE EASIER
Dr Yannick Baschung discusses the benefits and challenges of orally inhaled and nasal drug products and examines how drug developers can stress test their products to improve regulatory success and patient safety, as well as how partnering with an expert CRO can provide an efficient way of performing critical characterisation testing.
DISSOLUTION TESTING FOR ORALLY INHALED PRODUCTS: CONFRONTING THE CHALLENGES, REALISING THE POTENTIAL
EXPERT VIEW
Jamie Clayton
DISSOLUTION TESTING FOR ORALLY INHALED PRODUCTS: CONFRONTING THE CHALLENGES, REALISING THE POTENTIAL
As dissolution testing rises up the agenda for orally inhaled product developers, Jamie Clayton explores drivers behind its adoption and key considerations for developing a robust and relevant method.
INHALED OLIGONUCLEOTIDES – THE FUTURE FOR RESPIRATORY DISEASES
PULMONARY
Dr Philippe Rogueda
Merxin Ltd
INHALED OLIGONUCLEOTIDES – THE FUTURE FOR RESPIRATORY DISEASES
Dr Philippe Rogueda discusses the therapeutic potential promised by oligonucleotides and presents the case for prioritising the inhalation route as the ideal delivery mechanism for these drugs, highlighting how direct delivery to the lungs via devices such as dry power inhalers or soft mist inhalers can maximise the therapeutic efficacy and minimise the side effects of these exciting drugs.
HOW CUTTING EDGE IN SILICO APPROACHES CAN REDUCE TIME AND RISK IN DEVELOPMENT OF INHALATION DEVICES
EXPERT VIEW
Dr Peter Harley
HOW CUTTING EDGE IN SILICO APPROACHES CAN REDUCE TIME AND RISK IN DEVELOPMENT OF INHALATION DEVICES
Dr Peter Harley, Mariam Al-Amari and Matt Jones explore how in silico approaches can transform pulmonary and nasal drug delivery device development, illustrating through case studies – spanning low-global-warming potential propellants, assembly robustness, device-user interaction, variability and capsule piercing dynamics – how simulation-led in silico approaches can improve understanding of device performance and identify risks early, reducing development costs and accelerating the path to more reliable, innovative and patient-friendly drug-device systems.
DELIVERING AND MAINTAINING OPTIMAL DPI PERFORMANCE
EXPERT VIEW
Chris Gilmor
DELIVERING AND MAINTAINING OPTIMAL DPI PERFORMANCE
Chris Gilmor considers the issues affecting dry powder inhalers and explains how formulators use a range of techniques to ensure dose dispersion and API detachment. He goes on to explain the importance of controlling the moisture level in these devices and how it can affect the drug delivery performance of the formulation.
CLEARING THE AIR(WAY): DEBUNKING THREE COMMON MYTHS ABOUT INHALED DRUG DELIVERY
PULMONARY
Dr Keat Theng Chow
Roquette
CLEARING THE AIR(WAY): DEBUNKING THREE COMMON MYTHS ABOUT INHALED DRUG DELIVERY
Dr Keat Theng Chow and Susana Ecenarro explore three myths surrounding inhalation as a route of administration, clearing the way for a deeper understanding of one of pharma’s most exciting areas for innovation.
Interview: Integrating Phillips Medisize and Vectura’s Operations
INTERVIEW
Charlie Schumacher
Phillips Medisize
Interview: Integrating Phillips Medisize and Vectura’s Operations
In this interview, Charlie Schumacher and Sandy Munro discuss Phillips Medisize’s progress on its integration of Vectura, covering aspects such as cultural alignment, technical innovation and the evolving role of CDMOs in the inhalation landscape.
ADVANCING ELASTOMER SEAL SOLUTIONS FOR THE PRESSURISED METERED DOSE INHALER MARKET
INDUSTRIALISATION
Nathan Sowder
Parker O-Ring & Engineered Seals Division
ADVANCING ELASTOMER SEAL SOLUTIONS FOR THE PRESSURISED METERED DOSE INHALER MARKET
Nathan Sowder discusses Parker O-Ring & Engineered Seals Division’s role and history in providing advanced elastomer seals and components to the drug delivery industry, with a particular emphasis on pressurised metered dose inhalers.
FACILITY SPOTLIGHT: UK-BASED CAPABILITIES IN INHALED AND NASAL DRUG-DEVICE PRODUCT DEVELOPMENT
RESPIRATORY
Ross Errington
Bespak
FACILITY SPOTLIGHT: UK-BASED CAPABILITIES IN INHALED AND NASAL DRUG-DEVICE PRODUCT DEVELOPMENT
Ross Errington introduces Bespak’s Holmes Chapel (UK) site, which is equipped to support device development programmes from early-stage formulation to large-scale manufacture.
ORBITAL: A NOVEL HIGH-PAYLOAD, MULTI-BREATH DPI POISED FOR CLINICAL ADVANCEMENT
RESPIRATORY
David Farrow
Aptar Pharma
ORBITAL: A NOVEL HIGH-PAYLOAD, MULTI-BREATH DPI POISED FOR CLINICAL ADVANCEMENT
David Farrow, Jonathan Mulpas and Solange Le Nuz discuss the patient-centric and data-driven development of Aptar Pharma’s Orbital dry powder inhaler platform, tracing its evolution from an initial concept to a clinically-ready device.
NAVIGATING THE REGULATORY PATHWAY FOR NEXT-GENERATION NEBULISERS IN COMBINATION WITH BIOLOGICS
CONNECTIVITY
Edgar Hernan Cuevas Brun
HCmed Innovations
NAVIGATING THE REGULATORY PATHWAY FOR NEXT-GENERATION NEBULISERS IN COMBINATION WITH BIOLOGICS
Edgar Hernan Cuevas Brun discusses the role of nebulisers in delivering larger doses of fragile biologics, delving into the global regulatory landscape that must be understood in order to deliver these drugs on the market.
ENHANCING DRUG DELIVERY WITH INNOVATIVE SOFT MIST INHALER TECHNOLOGY
PULMONARY
Dr Nicolas Buchmann
Resyca
ENHANCING DRUG DELIVERY WITH INNOVATIVE SOFT MIST INHALER TECHNOLOGY
Dr Nicolas Buchmann and Bernhard Müllinger, discuss the capabilities of soft mist inhalers in terms of usability for patients, sustainability, compatibility with biologics and cost-effective delivery, showcasing these advantages in Resyca’s Pre-Filled Syringe Inhaler (PFSI).
EXPANDING OPPORTUNITIES FOR INHALED DRUG DELIVERY
PULMONARY
Dr Gunilla Petersson
Nanoform
EXPANDING OPPORTUNITIES FOR INHALED DRUG DELIVERY
Dr Gunilla Petersson considers the challenges associated with efficiently delivering drugs to the lungs and the potential of nanoparticle-based formulations to achieve high lung deposition of small molecules and biologics, using gentle particle processing techniques that enable the delivery of sensitive drugs.
Top